Author

Chandru Gajendran

Observed names: C. Gajendran, Chandru G, G. Chandru

ORCID: 0000-0001-6357-9214

Observed ORCID: 0000-0001-6357-9214

OpenAlex ID: A5028330105

A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2022 · Hui Deng, Cindy Lin, et al. · Cancer Research · 95

Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4

2023 · Chandru Gajendran, Shoichi Fukui, et al. · Scientific Reports · 72

Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma

2020 · M Naveen Sadhu, Dhanalakshmi Sivanandhan, et al. · Bioorganic & Medicinal Chemistry Letters · 41

Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer

2023 · Chandru Gajendran, Subramanyam Janardhan Tantry, et al. · PLoS ONE · 22

Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer

2020 · Dhanalakshmi S, Sridharan Rajagopal, et al. · Blood · 13

Novel, small molecule inhibitors of PD-1/PD-L1 pathway.

2022 · Luca Rastelli, Sridharan Rajagopal, et al. · Journal of Clinical Oncology · 9

Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors

2020 · Natarajan Tamizharasan, Chandru Gajendran, et al. · Bioorganic Chemistry · 9

Abstract 6269: JBI-778, a novel brain-penetrant small molecule PRMT5 inhibitor for treatment of cancer

2023 · Dhanalakshmi Sivanandhan, Chandru Gajendran, et al. · Cancer Research · 4

Abstract B029: LSD1-HDAC6 dual inhibitor JBI-802 is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumor types

2022 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Cancer Research · 3

Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis

2022 · S. Dhanalakshmi, S. Rajagopal, et al. · European Journal of Cancer · 2

Abstract 2646: Novel, isoform selective PAD4 inhibitors for the treatment of cancer

2022 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Cancer Research · 2

Abstract 11: Novel dual inhibitors of LSD1-HDAC6/8 for treatment of cancer

2019 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Cancer Research · 2

Anti-tumor activity of CoREST inhibitor, JBI-802 (dual epigenetic modifier of LSD1/HDAC6): An opportunity to treat essential thrombocythemia and MPN/MDS patients with thrombocytosis in ongoing phase 1/2 clinical trial.

2025 · Melda S. Dolan, Sridharan Rajagopal, et al. · Journal of Clinical Oncology · 1

JBI802 a Highly Potent Corest Inhibitor Demonstrated Anti-Tumor Activity at Low Dose, Thrombocytopenia at Higher Dose NOW Leading to an Opportunity to Treat ET Myeloproliferative Neoplasms (MPN) /Essential Thrombocythemia [ET]) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis

2024 · Melda Dolan, Sridharan Rajagopal, et al. · Blood · 1

Abstract 5860: Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer

2018 · Dhanalakshmi Sivanandhan, Sreekala Nair, et al. · Cancer Research · 1

Abstract 4388: Novel small molecule on state inhibitor for GTP bound pan-KRAS (G12) mutations

2025 · Chandru Gajendran, Naveen M. Sadhu, et al. · Cancer Research

Data from A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2023 · Hui Deng, Cindy Lin, et al.

Supplementary Figure from A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2023 · Hui Deng, Cindy Lin, et al.

Supplementary Figure from A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2023 · Hui Deng, Cindy Lin, et al.

Supplementary Data from A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2023 · Hui Deng, Cindy Lin, et al.

Supplementary Data from A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression

2023 · Hui Deng, Cindy Lin, et al.

1376 Novel, brain penetrant small molecule inhibitor of PD-L1 for targeting glioblastoma and brain metastasis

2022 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Journal for ImmunoTherapy of Cancer

1386 Novel gut-restricted small molecule inhibitor of PD-L1 for targeting GI cancers

2022 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Journal for ImmunoTherapy of Cancer

Abstract 1128: Selective, novel, small molecule PRMT5 inhibitors for treatment of cancer

2021 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Cancer Research

Abstract 1630: Novel, small molecule inhibitors of PD-L1/PD-1 interaction

2021 · Dhanalakshmi Sivanandhan, Sridharan Rajagopal, et al. · Cancer Research

Works count: 27

Citation count: 277

H-index: 7

I10-index: 5